Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind's psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: ...
The administration of intranasal medications alleviated nasal symptoms and was safe for treating seasonal and perennial allergic rhinitis (AR) in children, although they appeared less effective than ...
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative ...
Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results